AXON - Axovant Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Axovant Sciences Ltd.

11-12 St. James's Square
Suite 1, 3rd Floor
London SW1Y 4LB
United Kingdom
44 20 3318 9708

Full Time Employees45

Key Executives

NameTitlePayExercisedYear Born
Dr. Pavan Cheruvu M.D.CEO & DirectorN/AN/A1982
Dr. Gregory M. WeinhoffPrincipal Financial & Accounting Officer561.03kN/A1971
Mr. Mark AltmeyerPres & Chief Commercial Officer of Axovant Sciences GmbHN/AN/A1961
Dr. David T. HungScientific Advisor of GroupN/AN/A1958
Dr. Fraser WrightChief Technology OfficerN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Corporate Governance

Axovant Sciences Ltd.’s ISS Governance QualityScore as of October 1, 2018 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.